PLOD2: A Potential Drug Target and Biomarker (G5352)

Target Name: PLOD2

NCBI ID: G5352

PLOD2

PLOD2: A Potential Drug Target and Biomarker

Plasma kallikrein (PLOD2) is a protein that is expressed in various tissues and cells of the body. It is a potent anticoagulant, which means that it helps to prevent blood clots from forming. In addition, PLOD2 has been shown to play a role in the regulation of blood pressure, and it has been linked to the development of certain diseases, such as heart failure and liver cancer.

As a potential drug target, PLOD2 is an attractive target for researchers because it has a well-established function in the body and because it is involved in several important physiological processes. Additionally, because PLOD2 is a transmembrane protein, which means that it is involved in the production of the plasma membrane, it is potential to target using small molecules or antibodies that can be administered directly to the body.

One of the key challenges in studying PLOD2 as a potential drug target is its complex structure. PLOD2 is a member of the kallikrein gene family, which includes several other proteins that are involved in the regulation of platelet function and blood clotting. These proteins have a high degree of sequence variation and multiple isoforms, which can make it difficult to study the molecular mechanisms of their function.

However, research into PLOD2 has identified several potential drug targets. For example, several studies have shown that PLOD2 can be activated by small molecules that are derived from natural compounds, such as fruits and vegetables. These compounds have been shown to be effective in inhibiting the activity of PLOD2 and have the potential to be used as drug candidates.

Another potential drug target for PLOD2 is its role in the regulation of blood pressure. Several studies have shown that PLOD2 plays a key role in the regulation of blood pressure by controlling the activity of smooth muscle cells in the walls of blood vessels. This suggests that PLOD2 may be a useful target for drugs that are designed to improve blood pressure.

Additionally, PLOD2 has also been shown to be involved in the development of certain diseases, such as heart failure and liver cancer. Studies have shown that PLOD2 is expressed in the hearts of patients with heart failure and that it is involved in the regulation of cellular processes that are important for the development and progression of heart failure. Similarly, PLOD2 has also been shown to be involved in the regulation of liver function in patients with liver cancer.

Overall, PLOD2 is a protein that has the potential to be a drug target and biomarker. Its well-established function in the body and its involvement in several important physiological processes make it an attractive target for researchers. Additionally, its transmembrane structure and the potential to target using small molecules or antibodies make it a promising candidate for drug development. Further research is needed to fully understand the molecular mechanisms of PLOD2's function and its potential as a drug target.

Protein Name: Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2

Functions: Forms hydroxylysine residues in -Xaa-Lys-Gly- sequences in collagens. These hydroxylysines serve as sites of attachment for carbohydrate units and are essential for the stability of the intermolecular collagen cross-links

The "PLOD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PLOD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets